The 2025 FDA label expansion allows SPRAVATO® alone for adults with treatment-resistant depression. Supervised treatment and safety requirements still apply.
A label expansion, not a new medication
On January 21, 2025, FDA expanded the approved use of SPRAVATO® to include treatment-resistant depression in adults without a concurrent oral antidepressant. The FDA approval letter describes the change as an expansion to monotherapy. This article explains that earlier action; it is not a new approval announced today.
Monotherapy means using this treatment without an accompanying oral antidepressant. The current prescribing information, revised March 2026, permits SPRAVATO® either alone or with an oral antidepressant for adult treatment-resistant depression. It does not mean that everyone with depression qualifies or should change an existing prescription.
The two approved indications are different
The monotherapy option applies to adult treatment-resistant depression. The separate indication for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior still specifies use with an oral antidepressant. Those are distinct approved uses, not interchangeable instructions.
The label also states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. Improvement after a dose does not remove the need for hospitalization when clinically warranted. SPRAVATO® is not approved for pediatric patients.
Supervision and boxed warnings still apply
SPRAVATO® remains subject to its Risk Evaluation and Mitigation Strategy, or REMS. It is administered under healthcare supervision in a certified setting, with monitoring for at least two hours. This is not a take-home nasal spray.
The boxed warning covers sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors. The antidepressant warning includes increased risk of suicidal thoughts and behaviors in pediatric and young adult patients. Blood pressure assessment and restrictions on driving also remain important: the label says not to drive until the next day after restful sleep. These requirements did not disappear with monotherapy approval.
What the evidence does—and does not—show
The prescribing information describes a randomized, placebo-controlled monotherapy study in adults with treatment-resistant depression. It supports the approved option; it does not show that every patient will respond, that treatment is risk-free, or that it is better than every other depression treatment. This approval also does not make IV or other non-SPRAVATO® ketamine treatments FDA-approved for depression.
Questions for a psychiatric clinic
Our editorial interpretation is that the expanded indication creates another discussion point for adults whose depression has not responded adequately to prior treatment. It is not a recommendation to stop an oral antidepressant. Ask the clinic which indication applies, how prior treatments are assessed, what monitoring involves, and how insurance authorization is handled. FDA approval alone does not establish coverage under a particular plan.
Read our SPRAVATO® treatment guide and insurance and cost overview, or find psychiatric clinics. For immediate danger call 911; for suicidal thoughts or emotional distress, call or text 988.
Source check: October 13, 2026. Written and reviewed by the Psychiatry Clinics editorial team against the FDA approval letter, current prescribing information, and official REMS materials.
This page is informational and is not medical advice.
More reporting on treatment updates.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.